Latest amnestic mild cognitive impairment Stories
AGB101 could be the first drug to modify progression of amnestic mild cognitive impairment (aMCI) in patients at a high-risk for progressing to Alzheimer's dementia NEW YORK, Jan.
Phase 3-ready AGB101 designed to address aMCI, the pre-dementia stage of Alzheimer's Disease BALTIMORE, Jan.
It can be difficult to distinguish between people with normal age-associated memory loss and those with amnestic mild cognitive impairment (aMCI).
NEW YORK, Aug. 26 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc.
CHICAGO, ILLINOIS--(Marketwire - July 30, 2008) - Allon Therapeutics Inc.
CHICAGO, ILLINOIS--(Marketwire - July 28, 2008) - Allon Therapeutics Inc.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.